Adenoviral vectors for gene transfer and therapy

被引:171
作者
Volpers, C
Kochanek, S
机构
[1] Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany
[2] Univ Cologne, ZMMK, Ctr Mol Med, D-50931 Cologne, Germany
[3] Univ Cologne, Inst Genet, D-50931 Cologne, Germany
关键词
adenovirus; adenoviral vectors; nuclear entry; gene expression; immunogenicity; gene therapy;
D O I
10.1002/jgm.496
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Due to the very efficient nuclear entry mechanism of adenovirus and its low pathogenicity for humans, adenovirus-based vectors have become gene delivery vehicles that are widely used for transduction of different cell types, especially for quiescent, differentiated cells, in basic research, in gene therapy applications, and in vaccine development. As an important basis for their use as gene medicine, adenoviral vectors can be produced in high titers, they can transduce cells in vivo with transgenes of more than 30 kb, and they do not integrate into the host cell genome. Recent advances in the development of adenoviral vectors have brought considerable progress on issues like target cell specificity and tropism modification, long-term expression of the transgene, and have suggested that the as well as immunogenicity and toxicity in vivo, different generations of non-replicative and replicative vectors available today will each suit best for certain applications. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:S164 / S171
页数:8
相关论文
共 88 条
[1]   Blood clearance rates of adenovirus type 5 in mice [J].
Alemany, R ;
Suzuki, K ;
Curiel, DT .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2605-2609
[2]   Replicative adenoviruses for cancer therapy [J].
Alemany, R ;
Balagué, C ;
Curiel, DT .
NATURE BIOTECHNOLOGY, 2000, 18 (07) :723-727
[3]  
Anderson WF, 2002, HUM GENE THER, V13, P1, DOI 10.1089/10430340152712610
[4]   CHARACTERIZATION OF AN ADENOVIRUS GENE-TRANSFER VECTOR CONTAINING AN E4 DELETION [J].
ARMENTANO, D ;
SOOKDEO, CC ;
HEHIR, KM ;
GREGORY, RJ ;
STGEORGE, JA ;
PRINCE, GA ;
WADSWORTH, SC ;
SMITH, AE .
HUMAN GENE THERAPY, 1995, 6 (10) :1343-1353
[5]   Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector [J].
Balagué, C ;
Zhou, JM ;
Dai, YF ;
Alemany, R ;
Josephs, SF ;
Andreason, G ;
Hariharan, M ;
Sethi, E ;
Prokopenko, E ;
Jan, HY ;
Lou, YC ;
Hubert-Leslie, D ;
Ruiz, L ;
Zhang, WW .
BLOOD, 2000, 95 (03) :820-828
[6]   Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 [J].
Bergelson, JM ;
Cunningham, JA ;
Droguett, G ;
KurtJones, EA ;
Krithivas, A ;
Hong, JS ;
Horwitz, MS ;
Crowell, RL ;
Finberg, RW .
SCIENCE, 1997, 275 (5304) :1320-1323
[7]   Targeting of high-capacity adenoviral vectors [J].
Biermann, V ;
Volpers, C ;
Hussmann, S ;
Stock, A ;
Kewes, H ;
Schiedner, G ;
Herrmann, A ;
Kochanek, S .
HUMAN GENE THERAPY, 2001, 12 (14) :1757-1769
[8]   Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre [J].
Chen, LN ;
Anton, M ;
Graham, FL .
SOMATIC CELL AND MOLECULAR GENETICS, 1996, 22 (06) :477-488
[9]   A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus [J].
Cheshenko, N ;
Krougliak, N ;
Eisensmith, RC ;
Krougliak, VA .
GENE THERAPY, 2001, 8 (11) :846-854
[10]  
Clemens PR, 1996, GENE THER, V3, P965